25.07.2020 | ASO Author Reflections
ASO Author Reflections: Performance of Contralateral Risk-Reducing Mastectomy in Multigene Panel-Tested Patients is High in All Types of Germline Mutation Carriers
verfasst von:
Brittany L. Murphy, MD, MS, Isabelle Bedrosian, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Use of germline panel testing in patients with breast cancer has been rapidly expanding, which has resulted in the identification of a greater number of pathogenic mutations and variants of uncertain significance (VUS) in this population.
1‐
3 While the risk of contralateral breast cancer and the associated benefit of contralateral risk-reducing mastectomy (CRRM) have been well characterized in patients with BRCA 1/2 mutations, and such patients can thus be adequately counseled regarding the risk/benefit of surgical intervention, less is known about the risk of second primary breast cancer conferred by the majority of non-BRCA germline pathogenic mutations. Given the absence of such data for informed decision making, whether the finding of a non-BRCA germline mutation influences patient decision for CRRM is not clear. …